Home Biomedical research Cancer Drug Development: Optimizing the Pipeline

Cancer Drug Development: Optimizing the Pipeline

2
0

Watch this on-demand webinar for tips to improve the success of your research goals


Dr Catherine Ulich, Global Field Applications Scientist, Horizon Discovery

Biomedical researchers in pharmaceuticals, biotechnology and academia are spending approximately US $ 1 billion over 10 years to develop a new drug. Optimizing every step of the drug discovery pipeline, from target identification to the clinic, is critical to success, otherwise setbacks can occur, such as costly delays or, in the worst case, attrition to one. advanced stage. To overcome these potential challenges, solutions are continually being developed to move the process forward while minimizing risk.

In this free SelectScience® online seminar, now available on request, Dr Catherine Ulich, Global Field Applications Scientist at Horizon Discovery, explains how the company can help you accelerate your research, from discovery to clinical development, with its expertise in gene editing and modulation CRISPR and its complementary cellular services.

Read on for highlights from the Q&A discussion or Register now to watch the on-demand webinar

When should I use CRISPRi?

CU: CRISPRi technology sits between the CRISPR knockout and RNAi, in that it produces results that are as crisp and clean as using the CRISPR knockout. CRISPRi works by preventing transcription rather than targeted gene disruption. It may be more efficient at studying genes where low level residual expression might mask a critical phenotype.

CRISPRi is well suited to the study of hypomorphic phenotypes, as well as non-coding genes. To this end, Horizon recently developed a new set of reagents, the Horizon CRISPRi System, which uses a catalytically deactivated Cas9 that has fused with our proprietary transcriptional repressors, SALL1 and SDS3.

When we combine this with our algorithm design guides, we can target the gene immediately downstream of the transcription start site and repress it, and we can see inhibition within 24 hours.

Can you explain your cell panel selection process?

CU: We have 2D and 3D cell screening which we call OncoSignature. It is a consortium-like screening platform where customers can test single agent or combination agents and examine the activity of their treatments in all 300 or a subset of our OncoSignature cell line panel. .

With this service, customers can measure the impact of their treatments on cell viability with a single treatment time for a dose response. So, since this is a consortium service, we can complete a screen within three months and the final analyzed data is reported in the fourth month.

We also have the option of integrating customer lines and models, as well as looking at various displays, looking more at a custom cell panel display.

To learn more about common issues with the drug discovery and validation pipeline, watch the webinar on demand >>

SelectScience hosts more than 10 webinars per month on various scientific topics, find out more from our upcoming webinars >>


Source link